RNA viruses for immunovirotherapy

Patent metadata

Field	Value
Publication number	US-12303540-B2
Application number	US-202117166398-A
Country	US
Kind code	B2
Filing date	Feb 3, 2021
Priority date	Feb 25, 2014
Publication date	May 20, 2025
Grant date	May 20, 2025

Abstract

The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding a secreted activator of the immune response, to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.

First claim

The invention claimed is:

1. A polynucleotide encoding a recombinant measles virus, the polynucleotide comprising at least one expressible polynucleotide encoding a secreted activator of the immune response, wherein the secreted activator of the immune response is encoded by the nucleotide sequence depicted in SEQ ID NOs: 2, and/or 4, and wherein the recombinant measles virus is derived from the Edmonston B strain of measles virus.

2. The polynucleotide of claim 1 , further comprising a second expressible polynucleotide encoding a second secreted activator of the immune response.

3. The polynucleotide of claim 2 , wherein said second expressible polynucleotide encoding a secreted activator of the immune response is a cytokine or a second antagonist of an inhibitory factor of a T-cell or an antagonist of a negative immune regulator of the tumor-immune microenvironment.

4. A method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus encoded by the polynucleotide of claim 1 , thereby treating the cancer in the subject afflicted with cancer.

5. The method of claim 4 , further comprising contacting said subject with the polynucleotide encoding the recombinant virus.

6. A method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with the polynucleotide of claim 1 , thereby treating the cancer in the subject afflicted with cancer.

7. The method of claim 4 , wherein said cancer is a solid cancer, a metastasis, or a relapse thereof.

8. The method of claim 4 , wherein treating cancer is reducing tumor burden.

9. The method of claim 4 , wherein said cancer is malignant melanoma, head and neck cancer, hepatocellular carcinoma, pancreatic carcinoma, prostate cancer, renal cell carcinoma, gastric carcinoma, colorectal carcinoma, lymphomas or leukemias.

10. A kit comprising at least the recombinant virus encoded by the polynucleotide of claim 1 housed in a container.

11. A kit comprising at least the polynucleotide of claim 1 housed in a container.

12. The kit of claim 10 , further comprising the polynucleotide encoding the recombinant virus.

13. A pharmaceutically acceptable composition comprising a recombinant virus encoded by the polynucleotide of claim 1 and at least one pharmacologically acceptable excipient.

14. A pharmaceutically acceptable composition comprising the polynucleotide of claim 1 , and at least one pharmacologically acceptable excipient.

15. The pharmaceutically acceptable composition of claim 13 , further comprising the polynucleotide encoding the recombinant virus.

16. An in vitro method for activating immune cells in a sample comprising cancer cells and immune cells, comprising contacting said sample comprising cancer cells and immune cells with a recombinant virus encoded by the polynucleotide of claim 1 , thereby activating the immune cells comprised in said sample.

17. An in vitro method for activating immune cells in a sample comprising cancer cells and immune cells, comprising contacting said sample comprising cancer cells and immune cells with the polynucleotide of claim 1 , thereby activating the immune cells comprised in said sample.

18. The in vitro method for activating immune cells in a sample comprising cancer cells and immune cells of claim 16 , further comprising contacting said sample comprising cancer cells and immune cells with the polynucleotide encoding the recombinant virus, thereby activating the immune cells comprised in said sample.

Assignees

• Deutsches Krebsforschung Szentrum
• Univ Heidelberg Ruprecht Karls
• Deutsches Krebsforschung Szentrum Ruprecht Karls Univ Heidelberg

Inventors

• Engeland Christine
• Ungerechts Guy
• Bossow Sascha

Classifications

• C12N2760/18433

  Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory · CPC title

• A61K39/39558

  against tumor tissues, cells, antigens · CPC title

• C12N15/86

  Viral vectors · CPC title

• C12N2760/18441

  Use of virus, viral particle or viral elements as a vector · CPC title

• C12N2760/18471

  Demonstrated in vivo effect · CPC title